News
FDA asks Sarepta to stop shipping gene therapy
Digest more
The company refused the FDA’s request and will continue shipping its therapy, Elevidys, to Duchenne patients who can still ...
In light of recent patient deaths, the FDA has also revoked its platform designation for Sarepta’s AAVrh74 technology. The ...
Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an ...
The Sarepta saga continues, with the FDA slapping a clinical hold across all of the company’s investigational limb girdle ...
Sarepta stock has tanked. Most investors don’t see the drugmaker’s executive management as credible following the failure to disclose a patient death, a BMO survey suggests.
The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback